thiotepa has been researched along with Multiple Primary Neoplasms in 10 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This report describes and presents some preliminary results from a prospective clinical investigation to determine the ablative effect of thiotepa (N,N',N''-triethylene phosphoramide) on superficial low-stage bladder cancer and the effectiveness of this agent in the prevention of recurrent or new tumors." | 9.04 | The role of intravesical thiotepa in the management of superficial bladder cancer. National Bladder Cancer Collaborative Group A. ( , 1977) |
| "This report describes and presents some preliminary results from a prospective clinical investigation to determine the ablative effect of thiotepa (N,N',N''-triethylene phosphoramide) on superficial low-stage bladder cancer and the effectiveness of this agent in the prevention of recurrent or new tumors." | 5.04 | The role of intravesical thiotepa in the management of superficial bladder cancer. National Bladder Cancer Collaborative Group A. ( , 1977) |
| "Rapidly fatal acute myelogenous leukemia (AML) occurred in a woman with advanced (Stage III) ovarian carcinoma who was treated with thiotepa for 30 months." | 4.75 | Ovarian carcinoma terminating in acute nonlymphocytic leukemia following alkylating agent therapy. ( Kapadia, SB; Krause, JR, 1978) |
| "Chlorambucil and melphalan were the most leukemogenic drugs, followed by thiotepa; cyclophosphamide and treosulfan were the weakest leukemogens, and the effect per gram was substantially lower at high doses than at lower doses." | 2.67 | Leukemia following chemotherapy for ovarian cancer. ( Bell, J; Clarke, EA; Day, NE; Høst, H; Kaldor, JM; Karjalainen, S; Mehnert, W; Pedersen, D; Pettersson, F; Prior, P, 1990) |
| "No excess mortality from noncolorectal cancers was apparent, nor were there significant differences by treatment: TSPA (22/22), FdUrd (9/12), and surgery only (50/42)." | 2.65 | Late effects of low-dose adjuvant chemotherapy in colorectal cancer. ( Boice, JD; Fraumeni, JF; Greene, MH; Higgins, GA; Keehn, RJ, 1980) |
| "At the age of 84, chronic myelogenous leukemia (CML) developed." | 1.27 | Philadelphia-chromosome-negative chronic myelogenous leukemia with incomplete trisomy 1q following chemotherapy for ovarian carcinoma. ( Haubenstock, A; Kabakow, B; Kim, HJ; Malamud, SC; Perle, MA; Vizel-Schwartz, M; Zalusky, R, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (90.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Powder, JR | 1 |
| Mosberg, WH | 1 |
| Pierpont, RZ | 1 |
| Tatoyan, KB | 1 |
| Young, JD | 1 |
| Boice, JD | 1 |
| Greene, MH | 1 |
| Keehn, RJ | 1 |
| Higgins, GA | 1 |
| Fraumeni, JF | 1 |
| Kardinal, CG | 1 |
| Donegan, WL | 1 |
| Kulkarni, JN | 1 |
| Kamat, MR | 1 |
| Juvekar, RL | 1 |
| Kapadia, SB | 1 |
| Krause, JR | 1 |
| Kaldor, JM | 1 |
| Day, NE | 1 |
| Pettersson, F | 1 |
| Clarke, EA | 1 |
| Pedersen, D | 1 |
| Mehnert, W | 1 |
| Bell, J | 1 |
| Høst, H | 1 |
| Prior, P | 1 |
| Karjalainen, S | 1 |
| Haubenstock, A | 1 |
| Zalusky, R | 1 |
| Kim, HJ | 1 |
| Kabakow, B | 1 |
| Perle, MA | 1 |
| Malamud, SC | 1 |
| Vizel-Schwartz, M | 1 |
| Veenema, RJ | 1 |
| Romas, NA | 1 |
| Fingerhut, B | 1 |
| Li, R | 1 |
| Kim, K | 1 |
| Brendler, H | 1 |
2 reviews available for thiotepa and Multiple Primary Neoplasms
| Article | Year |
|---|---|
Ovarian carcinoma terminating in acute nonlymphocytic leukemia following alkylating agent therapy.
Topics: Adult; Aged; Female; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasms, Multiple Primary; Ova | 1978 |
Chemotherapy for bladder cancer.
Topics: Administration, Topical; Alkylating Agents; Blood Cell Count; Carcinoma, Papillary; Cystitis; Cystos | 1974 |
4 trials available for thiotepa and Multiple Primary Neoplasms
| Article | Year |
|---|---|
Late effects of low-dose adjuvant chemotherapy in colorectal cancer.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Floxuridine; Hu | 1980 |
Second cancers after prolonged adjuvant thiotepa for operable carcinoma of the breast.
Topics: Breast Neoplasms; Female; Humans; Mastectomy; Middle Aged; Neoplasms, Multiple Primary; Prospective | 1980 |
The role of intravesical thiotepa in the management of superficial bladder cancer. National Bladder Cancer Collaborative Group A.
Topics: Clinical Trials as Topic; Humans; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Postopera | 1977 |
Leukemia following chemotherapy for ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Case-Control Studie | 1990 |
4 other studies available for thiotepa and Multiple Primary Neoplasms
| Article | Year |
|---|---|
Bilateral primary carcinoma of the ureter: topical intraureteral thiotepa.
Topics: Administration, Topical; Carcinoma, Transitional Cell; Humans; Male; Middle Aged; Neoplasm Recurrenc | 1984 |
Use of intravesical thiotepa in superficial bladder tumours.
Topics: Administration, Topical; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Neopla | 1981 |
Philadelphia-chromosome-negative chronic myelogenous leukemia with incomplete trisomy 1q following chemotherapy for ovarian carcinoma.
Topics: Chromosomes, Human, 1-3; Female; Granulosa Cell Tumor; Humans; Leukemia, Myeloid; Middle Aged; Neopl | 1985 |
Multiple and recurrent epithelial tumors of the bladder in a child.
Topics: Child, Preschool; Cystoscopy; Humans; Male; Neoplasms, Multiple Primary; Papilloma; Thiotepa; Urethr | 1972 |